Trader Reports
____________________________________________________________
_
Dermisonics Develops Working Model of Antiseptic Wand In The
$1.2 Billion Wound Care Market
Now In Talks With U.S. Army to Build Battlefield Version
____________________________________________________________
_
Pr ofiled: Dermisonics Inc.
Se ctor: Conglomerates
Symbo l: DMSI
$0.47
We have reviewed this new stock in our listings and we are
more than excited. This company
has developed a new antiseptic delvery system that not only
makes the application of
antiseptic to wounds, its ability to penitrate deeper than
surface cover can actually
help prevent against needed amputations due to uncontrolled
infections.
It is no wonder the US Military is interested in bulding a
battlefield version to help
protect our soldiers by better equiping the field medics.
Just check out their website and reveiw the full news
release below. With an annoucement
like this in the market we are very excited to see where
this stock goes tomorrow.
The Headline s:
WEST CONSHOHOCKEN, Pa., Feb. 6 /CNW/ -- Dermisonics, Inc.
(OTC Bulletin Board: DMSI.OB),
a pioneer in the development of ultrasonic transdermal
drug-delivery technologies,
announced today that it has completed the first working
model of its A-Wand antiseptic
delivery system and is in talks with the Army Institute of
Surgical Research under the
Combat Casualty Care Research Program to develop a
battlefield version.
The A-Wand (TM) is a handheld, portable, ultrasonic wand
device for applying antiseptic
solutions to cuts, abrasions and wounds with a replaceable
Patch-Cap (TM), which holds
up to 40 ml of antiseptic solution. It uses alternating
ultrasonic waveforms to enlarge
the diameter of the skin pores enabling antiseptics to
permeate through the skin
(Stratum Corneum) into the dermis through the sweat pores.
Attacks Critical Problem of Infections in Wounded Soldiers
-- Infection is a major,
potentially lethal, battlefield hazard for wounded soldiers
before they can receive
full medical treatment in a hospital. The Medic on the scene
applies antiseptic and
bandages the wound but the antiseptic only affects the
outermost layers of the damaged
tissue. Infection frequently results and is a major cause of
amputations.
The A-Wand Encapsulates the Wounded Area with Antiseptic --
The A-Wand would be used by
Medics in the field, by Mash units and for follow-up wound
care to significantly reduce
this hazard. Through the use of the A-Wand's ultrasound
system, the antiseptic solution
is "pushed" to the deeper tissue where it can more
effectively fight infection by
surrounding and encapsulating the wounded area with
antiseptic. It also has the added
advantage of being able to penetrate scared tissue without
damaging this basic body
defense system.
Technology inventor and Dermisonics Executive Vice-President
Bruce Redding commented,
"The A-Wand represents a huge opportunity for
Dermisonics and the various patients who
could benefit from increased infection-resistant
technologies. Dermisonics especially
is pleased by the response from the US Army and we hope this
technology finds acceptance
in the field as soon as possible"
The Next Generation in the $1.2 Billion Wound Care Market --
The Company believes the
A-Wand will represent a significant shift in wound-care
medical science and will
fundamentally change the $1.2 billion wound-care market.
Industry Opportunity and Receptivity -- As a harbinger of
its immediate industry impact,
the Company has already received, in addition to the
military, strong indications of
interest from major companies in the pharmaceutical and
hospital fields.
Dermisonics is an intellectual property company and advanced
technology
incubator that is primarily focused on the ongoing
development, testing and
eventual commercialization of a transdermal patch that has
been designed to
facilitate the efficient and needle-free delivery of drugs
with large
molecular structures into the bloodstream. Its breakthrough
system, called
the U-Strip, is based on a radical integration of
microelectronics and
ultrasonic science with a product-carrying patch, and
represents a quantum
leap in non- invasive, transdermal delivery technology.
Tests have shown
that this system facilitates the transdermal delivery of
insulin as well as
potentially at least 175 other existing drugs that at
present cannot be
effectively delivered through the pores of the skin using
conventionally
available transdermal technology due to their large
molecular size. The
Company has also developed other portable ultrasonic systems
for
applications in the medical (Antiseptic Wand) and skin care
(U-Wand) fields.
Good Tradin g
______________
Information within this em ail contains 4rward l0 0king
statements within
the meaning of Section 27A of the Secu rities Act of
nineteen thirty three
and Section 21B of the Securi ties Exch ange Act of nineteen
thirty four. Any
statements that express or involve discussions with respect
to predi ctions,
expec tations, beli efs, pla ns, projec tions, objec tives,
goa ls, ass
umptions or future events or performance are not statements
of historical
fact and may be 4rward 1o0king statements. Don't rely on
them to make a
decision. As with many micr ocap st0c ks, today's com pany
has disclosable material
items you need to consider in order to make an informed and
intelligent
in_vest ment decision. These items include: a reliance on
loans from
offi cers, some related party transactions, a goin concern
opinion from its
auditor, no reven ues in its most recent quar ter, a large
accumulated deficit,
default on not es pay able that could cause the com pany to
lose its intellectual
property, and potential litigation over its technology. It
is not an operating comp any
and is going to need fin ancing. Read the Company's S E C
Fili ngs now, right now, before
you inve st. None of the material within this report shall
be construed as any kind of in
vestment advi ce or solicitat ion. Many of these small compa
nies are on the verge of
bankr uptcy. You can lose all your m0ny by in-ves ting in
this st0c k. In
compliance with the Securi ties Act of 19 33, Sec tion
17(b),we disclose the receipt of
four hundred twenty five thousand free trading shares
received from a third party, not
an officer, director or affiliate shareholder for our
services. We intend to sell our
stock now. This could cause the stock to go down, resulting
in losses for you. All
factual informa tion in this report was gathered from public
sources, including but
not limited to Comp any Pre ss Releas es and Fili ngs.
|